Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Acq. announced
Inv. presentation
Filed Chapter 11
|
|
Codiak BioSciences, Inc. (CDAK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/30/2022 |
8-K
| Quarterly results |
| 11/17/2021 |
8-K
| Investor presentation|
Docs:
|
"Codiak Reports Positive Initial Data for exoSTING ™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts - exoSTING resulted in localized STING pathway activation and dose-dependent immune activation - - Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and distal non-injected lesions - - Data on objective response rate and recommended Phase 2 dose selection for expansion anticipated 1H 2022 - - Codiak to host conference call and webcast today at 8:00 am ET - CAMBRIDGE, Mass., November 16, 2021 — Codiak BioSciences, Inc. , a clinical-sta...",
"Presentation, by Codiak BioSciences, Inc" |
|
|
|